LinaMax Tablet 2.5/850 mg
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
MFDS item code 202002373 · Approved 2020.04.04
This product's status changed to Expired on 2025.04.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes
This medication helps control blood sugar levels in patients with type 2 diabetes by using both linagliptin and metformin. When taken alongside dietary and exercise regimens, it can effectively manage blood sugar. This contributes to maintaining stable blood sugar levels. Therefore, this medication is used in the treatment of patients with type 2 diabetes.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antidiabetic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).
This medication has been reported to cause serious side effects such as lactic acidosis, and caution should be taken. It is contraindicated for individuals with allergies to the active ingredients or components, type 1 diabetes patients, and those with severe renal impairment. Use of this medication should be avoided in cases of acute conditions that may affect kidney function, such as dehydration, severe infections, or acute heart failure. Patients with poor liver function or gastrointestinal disorders, those in acute alcohol intoxication, or with alcohol dependence should also avoid using this medication. Pregnant or nursing women are advised not to take this medication. This medication entails a risk of hypoglycemia, especially when used together with sulfonylureas or insulin, which may cause blood sugar levels to drop too low. Patients with diminished kidney function should have regular kidney function tests before taking this medication, and it should not be used if kidney function is severely impaired. Acute pancreatitis or skin blistering conditions may occur, thus any persistent severe abdominal pain or abnormal skin symptoms during usage should be consulted with a doctor immediately. This medication may lower vitamin B12 levels, therefore it is advisable to regularly check for vitamin B12 deficiency when taken for extended periods. There may be interactions when taken with other medications; hence, it is crucial to inform healthcare providers of all current medications. Elderly individuals often experience decreased kidney function, so renal function should be monitored frequently, and dosage adjustments made if necessary. If planning a pregnancy or if currently pregnant, this medication should be avoided, and alternative treatment methods for blood sugar control should be considered. Children and adolescents are not recommended to use this medication as its safety and efficacy have not been sufficiently established. In cases of overdose, gastrointestinal symptoms and lactic acidosis may occur, necessitating immediate hospital treatment. This medication should be stored away from moisture and kept out of reach of children, and it is advisable not to transfer to another container.
Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficient vitamin B12, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, joint pain accompanied by severity and disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuritis, septicemia, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer’s dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, renal transplant failure, pneumonia, hypercholesterolemia, headache, drowsiness, chest discomfort, asthenia, epistaxis, oropharyngeal pain, voice disorder, nasal bleeding, androgenic alopecia, hyperhidrosis, hair loss, dermatitis, anxiety, insomnia, depression, hypertension, hearing loss, erectile dysfunction, goiter, confusional state, nocturia, pruritus, angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, dizziness, diabetic neuropathy, subdural effusion, palpitations, dry eye, cataract, ocular discomfort, allergic conjunctivitis, increased blood triglycerides, decreased hemoglobin, increased blood potassium, increased blood creatinine, increased blood creatine phosphokinase, insomnia, depression, hypertension, dizziness, benign prostatic hyperplasia
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture and should be stored in a tightly sealed container. Also, avoid very hot or very cold conditions, and store at room temperature between 1°C and 30°C.
A bright orange oval film-coated tablet with both sides convex.
For domestic use - 30 tablets/PTP [6 tablets/PTP x 5 pieces]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.